Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Webcasts|March 4, 2021
Solid Form Screening and Rational Cocrystal Design
Author(s)Lonza
***Live: Thursday, March 4 , 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET & Asia Pacific: Thursday, March 11, 2021 at 4pm JST | 3pm CST | 6pm AEST | 12:30pm IST*** Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. Review the underlying fundamentals of various screening methods and case studies on in-silico screening methods.*** On demand available after final airing until March 11, 2022.***
Register free:
Event Overview:
Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. Knowledge of the underlying fundamentals of polymorphism, hydrates/solvates, salts, and cocrystals is essential to establish an understanding of a drug substance and its solid-form throughout the drug development lifecycle.
In this webcast, experts will discuss many aspects of solid-form screening including in-silico screening, which can save time and speed up the solid-form development process. A case study will review in-silico screening of cocrystals of a pharmacophore using hydrogen bond energies and hydrogen bond propensities. A second case study will examine cocrystallization of nutraceuticals and their versatile use as coformers.
Key Learning Objectives:
1. Understand the importance of solid-form screening and the impact of form selection in pharmaceutical development.
2. Learn how solid-form services can accelerate drug development.
3. Understand the importance of different in-silico screening methods in solid-form development.
Speakers:
Michael Grass, Head, Solid Form Services, Lonza
Abhijeet Sinha, Senior Scientist, Lonza
Time and Date:
Thursday, March 4 , 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET
Asia Pacific: Thursday, March 11, 2021 at 4pm JST | 3pm CST | 6pm AEST | 12:30pm IST
On demand available after final airing until March 11, 2022
Sponsor: Lonza
Register free:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
3
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5